UNSPSC 51141589: Carbamazepine dihydrate

This classification denotes an anticonvulsant agent with the molecular formula C15H12N2O.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 78M1RMW7Q8, chemically known as 5h-dibenz(b,f)azepine-5-carboxamide, hydrate (1:2), but more generally known as carbamazepine dihydrate, which bears US NIH Compound Identifier 158856. European Medicines Agency schedules carbamazepine dihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06113MIG.

Most nations, for tariff purposes, schedule carbamazepine dihydrate under HS 29339930. SMILES: C1CCC2C(C1)C=CC3CCCCC3N2C(=O)N.O.O.

UNSPSC 51141589 Carbamazepine dihydrate is a Commodity code that sits at the lowest tier of the pharmaceutical taxonomy. The recent opportunities posted under this code show substantial mismatch with its nominal scope. The code nominally identifies a specific anticonvulsant active pharmaceutical ingredient; however, the recent state and local solicitations tagged to this code are actually procuring naloxone (opioid reversal agent), generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and direct-to-manufacturer prescription program infrastructure. The Seminole County, Florida IFB60459723LAS (due July 26, 2023) sought naloxone units and drug deactivation systems, the Minnesota Multistate Cooperative Purchasing Alliance RFP S1070000015802 (due March 26, 2026) requested multiple generic pharmaceuticals and OTC products through established wholesalers, and the Texas Health and Human Services Commission RFI HHS0017013 (posted April 3, 2026) solicited vendor capabilities for direct-to-manufacturer prescription programs. The issuers include county health departments, state HHS agencies, and cooperative purchasing alliances representing multiple state and local jurisdictions. This code reflects recent activity in Florida, Minnesota, Oregon, and Texas, though the pharmaceutical products actually being solicited do not consistently match carbamazepine dihydrate.

The code shows active procurement across state health agencies and county health departments, but the opportunities tagged to it do not align with the code's stated pharmaceutical ingredient. Seminole County's naloxone and drug deactivation procurement required quarterly deliveries with fixed-fee pricing, E-Verify compliance, and a three-month probationary termination period. MMCAP's generic pharmaceutical RFP mandates cGMP and Drug Supply Chain Security Act compliance, relationships with specific authorized wholesalers including AmerisourceBergen and Cardinal Health, and price competitiveness weighted at 75 percent of evaluation. The Texas RFI, as an exploratory information-gathering vehicle prior to formal RFP, sought vendor experience with direct contracting, negotiated net pricing models, and outcomes-based agreements. Set-aside designations are not specified across these opportunities. The mismatch between the code's nominal scope and the actual pharmaceutical products being solicited suggests that state and local buyers are either tagging opportunities incorrectly or that this code functions as a catch-all for pharmaceutical procurement activity rather than a specific ingredient-level classification.